Compare TG Therapeutics Inc (TGTX) vs Energy Select Sector SPDR Fund (XLE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Energy Select Sector SPDR Fund — how do they compare? TG Therapeutics Inc trades at $49.44 (market cap $7.64B), while Energy Select Sector SPDR Fund trades at $60.89. The key difference: Energy Select Sector SPDR Fund is trading nearer its 52-week high, TG Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| TGTX | XLE | |
|---|---|---|
Market Cap | $7.64B | — |
Sector | Health | — |
52-Week High | $59.06 | $62.57 |
52-Week Low | $26.94 | $42.33 |
Enterprise Value | $7.84B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
XLE trades at $61.03, up 1.4% today, with a bullish technical signal from moving averages and neutral oscillators. Recent news highlights a 40.52% 12-month rally driven by strong oil prices and geopolitical tensions, though Seeking Alpha rates it HOLD due to less attractive entry points. The ETF's performance is heavily influenced by top holdings like ExxonMobil and Chevron, which reported surging Q2 profits.
Outlook remains tied to oil price volatility and Middle East tensions, offering growth potential but with high sensitivity to supply disruptions. Risks include geopolitical instability and concentrated exposure to a few large-cap energy stocks, warranting caution despite bullish momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Energy Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as energy companies by the GICS®, including securities of companies from the following industries: oil, gas and consumable fuels; and energy equipment and services. It is non-diversified.
Read more on XLE →
